CD8A and neoplasm: Additionally, quality and quantity of pretreatment tumor infiltration of T cells, as characterized by ImmunoSign 21 (IS21; T cell gene expression signature (GES)) and by Immunoscore (immunohistochemistry (IHC) with CD3 and CD8 cells), associated positively with outcomes to CAR T cell therapy10.